HC Wainwright Predicts Lower Earnings for Lexeo Therapeutics

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for Lexeo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($3.22) for the year, down from their previous forecast of ($2.75). HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.00) EPS and FY2025 earnings at ($3.84) EPS.

LXEO has been the subject of several other reports. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and a consensus target price of $22.71.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $6.02 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a one year low of $5.80 and a one year high of $22.33. The company has a 50-day simple moving average of $8.91 and a two-hundred day simple moving average of $12.18. The firm has a market capitalization of $199.08 million and a PE ratio of -1.90.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC grew its position in shares of Lexeo Therapeutics by 9.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after acquiring an additional 210,047 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Lexeo Therapeutics during the 1st quarter valued at $75,000. American International Group Inc. bought a new stake in shares of Lexeo Therapeutics during the 1st quarter valued at $79,000. Vanguard Group Inc. grew its position in shares of Lexeo Therapeutics by 15.8% during the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after acquiring an additional 65,573 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after acquiring an additional 3,483 shares during the period. Institutional investors own 60.67% of the company’s stock.

Insider Activity at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 12,500 shares of company stock valued at $113,300 over the last 90 days. Corporate insiders own 4.50% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.